Rivastigmine in Parkinson's disease dementia

Stefania Lalli, Alberto Albanese

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Dementia associated with Parkinson's disease (PD) ultimately develops in approximately 70% of patients with PD older than 80 years of age. The neuropathology of PD dementia (PDD) is likely multifactorial and affects several neuronal populations. There is evidence that PDD is associated with a cholinergic deficit, supporting the therapeutic role of cholinesterase inhibitors, which are already first-line agents in the treatment of Alzheimer's disease. Open-label and small controlled studies suggested a clinical efficacy of cholinesterase inhibitors in PDD. One large randomized placebo-controlled trial of 541 patients demonstrated that oral rivastigmine improved cognition, attention and executive functions, activities of daily living and behavioral symptoms after 6 months of treatment. Rivastigmine is a dual cholinesterase inhibitor, being effective on both acetylcholinesterase and butyrylcholinesterase. This paper reviews the pharmacokinetic and pharmacodynamic properties of rivastigmine (oral and transdermal administration). It also reviews evidence on clinical efficacy, safety and tolerability of the oral administration in PDD patients at doses of 3-12 mg/day.

Original languageEnglish
Pages (from-to)1181-1188
Number of pages8
JournalExpert Review of Neurotherapeutics
Volume8
Issue number8
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Rivastigmine
Parkinson Disease
Dementia
Cholinesterase Inhibitors
Oral Administration
Cutaneous Administration
Butyrylcholinesterase
Behavioral Symptoms
Executive Function
Acetylcholinesterase
Activities of Daily Living
Cognition
Cholinergic Agents
Alzheimer Disease
Therapeutics
Randomized Controlled Trials
Pharmacokinetics
Placebos
Safety

Keywords

  • Cholinesterase inhibitor
  • Dementia
  • Lewy body disease
  • Parkinson's disease
  • Rivastigmine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Rivastigmine in Parkinson's disease dementia. / Lalli, Stefania; Albanese, Alberto.

In: Expert Review of Neurotherapeutics, Vol. 8, No. 8, 08.2008, p. 1181-1188.

Research output: Contribution to journalArticle

@article{9f3359554fe44479ad31f785a0705c37,
title = "Rivastigmine in Parkinson's disease dementia",
abstract = "Dementia associated with Parkinson's disease (PD) ultimately develops in approximately 70{\%} of patients with PD older than 80 years of age. The neuropathology of PD dementia (PDD) is likely multifactorial and affects several neuronal populations. There is evidence that PDD is associated with a cholinergic deficit, supporting the therapeutic role of cholinesterase inhibitors, which are already first-line agents in the treatment of Alzheimer's disease. Open-label and small controlled studies suggested a clinical efficacy of cholinesterase inhibitors in PDD. One large randomized placebo-controlled trial of 541 patients demonstrated that oral rivastigmine improved cognition, attention and executive functions, activities of daily living and behavioral symptoms after 6 months of treatment. Rivastigmine is a dual cholinesterase inhibitor, being effective on both acetylcholinesterase and butyrylcholinesterase. This paper reviews the pharmacokinetic and pharmacodynamic properties of rivastigmine (oral and transdermal administration). It also reviews evidence on clinical efficacy, safety and tolerability of the oral administration in PDD patients at doses of 3-12 mg/day.",
keywords = "Cholinesterase inhibitor, Dementia, Lewy body disease, Parkinson's disease, Rivastigmine",
author = "Stefania Lalli and Alberto Albanese",
year = "2008",
month = "8",
doi = "10.1586/14737175.8.8.1181",
language = "English",
volume = "8",
pages = "1181--1188",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Rivastigmine in Parkinson's disease dementia

AU - Lalli, Stefania

AU - Albanese, Alberto

PY - 2008/8

Y1 - 2008/8

N2 - Dementia associated with Parkinson's disease (PD) ultimately develops in approximately 70% of patients with PD older than 80 years of age. The neuropathology of PD dementia (PDD) is likely multifactorial and affects several neuronal populations. There is evidence that PDD is associated with a cholinergic deficit, supporting the therapeutic role of cholinesterase inhibitors, which are already first-line agents in the treatment of Alzheimer's disease. Open-label and small controlled studies suggested a clinical efficacy of cholinesterase inhibitors in PDD. One large randomized placebo-controlled trial of 541 patients demonstrated that oral rivastigmine improved cognition, attention and executive functions, activities of daily living and behavioral symptoms after 6 months of treatment. Rivastigmine is a dual cholinesterase inhibitor, being effective on both acetylcholinesterase and butyrylcholinesterase. This paper reviews the pharmacokinetic and pharmacodynamic properties of rivastigmine (oral and transdermal administration). It also reviews evidence on clinical efficacy, safety and tolerability of the oral administration in PDD patients at doses of 3-12 mg/day.

AB - Dementia associated with Parkinson's disease (PD) ultimately develops in approximately 70% of patients with PD older than 80 years of age. The neuropathology of PD dementia (PDD) is likely multifactorial and affects several neuronal populations. There is evidence that PDD is associated with a cholinergic deficit, supporting the therapeutic role of cholinesterase inhibitors, which are already first-line agents in the treatment of Alzheimer's disease. Open-label and small controlled studies suggested a clinical efficacy of cholinesterase inhibitors in PDD. One large randomized placebo-controlled trial of 541 patients demonstrated that oral rivastigmine improved cognition, attention and executive functions, activities of daily living and behavioral symptoms after 6 months of treatment. Rivastigmine is a dual cholinesterase inhibitor, being effective on both acetylcholinesterase and butyrylcholinesterase. This paper reviews the pharmacokinetic and pharmacodynamic properties of rivastigmine (oral and transdermal administration). It also reviews evidence on clinical efficacy, safety and tolerability of the oral administration in PDD patients at doses of 3-12 mg/day.

KW - Cholinesterase inhibitor

KW - Dementia

KW - Lewy body disease

KW - Parkinson's disease

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=49449091311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449091311&partnerID=8YFLogxK

U2 - 10.1586/14737175.8.8.1181

DO - 10.1586/14737175.8.8.1181

M3 - Article

VL - 8

SP - 1181

EP - 1188

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 8

ER -